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Abstract
Background: Growing evidence exists for soluble Angiotensin Converting Enzyme-2 (sACE2) as a biomarker in definitive
heart failure (HF), but there is little information about changes in sACE2 activity in hypertension with imminent heart failure
and in reverse remodeling.
Methods, Findings: Patients with systolic HF (NYHAII-IV, enrolled for cardiac resynchronisation therapy, CRT, n = 100) were
compared to hypertensive patients (n = 239) and to a healthy cohort (n = 45) with preserved ejection fraction (EF.50%) in a
single center prospective clinical study. The status of the heart failure patients were checked before and after CRT.
Biochemical (ACE and sACE2 activity, ACE concentration) and echocardiographic parameters (EF, left ventricular end-
diastolic (EDD) and end-systolic diameter (ESD) and dP/dt) were measured. sACE2 activity negatively correlated with EF
and positively with ESD and EDD in all patient’s populations, while it was independent in the healthy cohort. sACE2 activity
was already increased in the hypertensive group, where signs for imminent heart failure (slightly decreased EF and barely
increased NT-proBNP levels) were detected. sACE2 activities further increased in patients with definitive heart failure (EF,
50%), while sACE2 activities decreased with the improvement of the heart failure after CRT (reverse remodeling). Serum
angiotensin converting enzyme (ACE) concentrations were lower in the diseased populations, but did not show a strong
correlation with the echocardiographic parameters.
Conclusions: Soluble ACE2 activity appears to be biomarker in heart failure, and in hypertension, where heart failure may be
imminent. Our data suggest that sACE2 is involved in the pathomechanism of hypertension and HF.
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Introduction
The renin–angiotensin system (RAS) is a central regulator of
cardiovascular and renal functions and plays an important role in
the pathophysiology of heart failure [1] [2]. Soluble Angiotensin
converting enzyme 2 (sACE2) is a recently discovered homologue
of ACE. It is a monocarboxypeptidase generating Ang-(1–9) from
Ang-I [3] and Ang-(1–7) from Ang-II. Ang-(1–7) is a biologically
active metabolite of the RAS acting through the G-protein-
coupled Mas receptor [4]. Ang-(1–7) is capable of reducing
myocardial oxidative stress and pathological remodeling [5]. Mas
receptor can hetero-oligomerize with AT1R acting as a physio-
logical antagonist of AngII [6].
In the heart, sACE2 is expressed in various cell types including
fibroblasts, cardiomyocytes and endothelial cells [7]. Although
sACE2 is a plasma membrane-bound ectoenzyme, a soluble active
form of the protein was also found in plasma and urine [8]. Tumor
necrosis factor alpha converting enzyme (TACE/ADAM17) is the
sheddase responsible for the ectodomain cleavage and shedding of
sACE2 [9].
Opposite to the AngI-ACE-AngII-AT1R pathway sACE2 may
provide a vasoprotective/antiproliferative mechanism resulting in
the counter-regulation of the RAS [10]. In accordance, previous
animal data have shown that transgenic sACE2 overexpression
attenuates hypertension [11] [12]. Suppression of sACE2 expres-
sion again established it as a negative regulator of the RAS in
blood pressure control [11] [13] [14]. Moreover, sACE2
polymorphisms were related to hypertension in different human
populations [15] [16] [17]. Nonetheless, the expression and
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activity of sACE2 in human hypertension has not been addressed
directly yet.
In contrast to hypertension, sACE2 has already been studied in
animal and human HF suggesting a protective role for this enzyme
[18]. Targeted disruption of sACE2 in mice results in severe
cardiac contractility defect, increased plasma and heart AngII
levels leading to cardiac dysfunction. Absence of sACE2 causes
stress activation of the myocardial NADPH oxidase system and
leads to severe adverse myocardial remodeling and dysfunction
[19]. It was suggested that myocardial sACE2 gene expression is
increased in patients with left ventricular dysfunction [20] and
TACE is also upregulated in HF [9]. Loss of sACE2 worsened the
pathological remodeling and resulted in a rapid progression to
systolic dysfunction and HF [21].
Epelman et al. showed that increased sACE2 activity is
associated with more advanced HF and that elevated sACE2
activity could predict adverse cardiac events [8]. Lehmann et al.
recently observed higher sACE2 activity in HF-patients experi-
encing ventricular arrhythmias and appropriate defibrillator-
intervention [22]. Whether these considerable correlations make
sACE2 activity suitable as a novel biomarker of heart failure is still
not settled.
Growing evidence exists for irrefutable importance of sACE2 in
the pathophysiology of HF, however there is little information
about changes in sACE2 activity during the progression of the
disease as well as about reverse changes under medical therapy
such as Cardiac Resynchronization Therapy (CRT).
Here we report a single center, prospective clinical study to
establish a relationship between circulating ACE, sACE2 and
clinical parameters, such as hypertension or cardiac performance.
Considering that use of terms related to ACE enzyme-activity and
enzyme-level occurs inconsistently in the literature, we performed
parallel ACE enzyme activity and enzyme concentration mea-
surements. We have studied these relationships in patients with
severe remodeling and during reverse remodeling when improved
systolic function was achieved by biventricular pacemaker device
therapy. sACE2 activity was measured in hypertensive patients for
the first time, and sACE2 was identified as a biomarker of
imminent heart failure, when cardiac ejection fraction is above
50%, but deterioration of cardiac performance is expected (e.g. in
patients with hypertension).
Methods
Study populations
Written informed consent has been obtained from the patients
and all clinical investigation has been conducted according to the
principles expressed in the Declaration of Helsinki. The study has
been approved by the Regional and Institutional Ethics Commit-
tee, Medical and Health Science Center, University of Debrecen,
(UDMHSC REC/IEC number: 3261–2010) and by the Medical
Research Council of Hungary.
A single center, prospective clinical study was performed at the
Institute of Cardiology of the University of Debrecen to investigate
the relationship between serum sACE2 activity and cardiovascular
pathologies, among other parameters.
There were three study groups. Healthy individuals (n = 45)
without any cardiovascular pathology or medication were
recruited with normal cardiac morphology and left ventricular
ejection fraction above 50%.
A second group of 239 hypertensive patients (systolic blood
pressure above 140 mmHg and/or diastolic blood pressure above
90 mmHg at the time of the diagnosis of the disease) was
established. This group was characterized by preserved ejection
fraction (above 50%) besides optimal antihypertensive therapy
according to the national guidelines (Table 1).
Table 1. Clinical characteristics of the study patients.
Variables Healthy people n=45 Hypertensive patients n=239
Heart failure (HF-CRT before)
n =100
Age, years (mean6SD) 30.268.7 62.369.6* 63.5610.8*#
Gender: men, % 45 59 79
Echocardiographic mesurements (mean6SD)
EF, % 62.064.2 56.664.5* 28.365.4*#
EDD, mm 48.663.9 51.765.7* 67.269.2*#
ESD, mm 29.963.6 33.465.4* 56.369.3*#
dP/dt, mmHg/s - - 498.2627.1
Cardiovascular risk factors, %
Hypertension 0 100 69
Diabetes 0 23 26
Dyslipidemia 0 70 71
Medication at enrollment, %
ACE inhibitor 0 83 89
ARB 0 15 11
b-Blocker 0 79 100
Aldosterone antagonist 0 6 89
Diuretics 0 53 91
NT-proBNP level, pmol/L 6.564.8 32.5669.4* 394.66522.7*#
*:healthy vs. others.
#:hypertensive vs. CRT before.
doi:10.1371/journal.pone.0087845.t001
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A third group of 100 patients with severe left ventricular systolic
dysfunction with indication of cardiac resynchronization therapy
(heart failure, HF) were also enrolled into the study (HF - CRT
before). Patients were selected for CRT according to the current
ESC guideline related to pharmaceutical and device therapy of
systolic heart failure [23,24] Till the date 65 patients fulfilled the
first visit between 6 and 9 months (HF - CRT after), so statistical
analyses and diagrams contain exclusively their data. Significant
mitral regurgitation was present in 22 patients, enabling dP/dt
measurements.
Examinations were performed at the enrollment (healthy
group), at regular visits (hypertensive group) or just before (HF -
CRT before group) and between 6 and 9 months after CRT
device implantation (HF – CRT after group). Each visit included
physical examination with assessment of New York Heart
Association (NYHA) functional stage, echocardiographic mea-
surements and blood sample collection for biochemical measure-
ments. Cardiovascular risk assessment comprised age, sex,
hypertension, hypercholesterinaemia, diabetes mellitus or ischae-
mic cardiomyopathy (Table 1). NYHA classification was per-
formed by independent clinicians who were not aware of
echocardiographic data. Medical reports and medication history
were obtained from all patients.
Echocardiographic measurements
Transthoracic echocardiography was performed using an
Accuson Sequoia (Siemens AG, Germany) echocardiograph.
Two dimensional and Doppler imaging was performed in
standard parasternal and apical views. The left ventricular ejection
fraction (EF) was measured by M mode left ventricular dimen-
sional method. Preserved EF cutoff was .50%. Values for dP/dt
(a functional parameter which is related to left ventricular
contractility) were determined in patients with severe mitral
regurgitation. Two experienced cardiologists unaware of the
biochemical data performed the echocardiographic measure-
ments.
Blood sample collection
Blood samples were collected by using a standard aseptic
technique. Native blood was incubated for 60 minutes at room
temperature. Serum fractions were separated by centrifugation
(1,500 g, 15 min) and kept in a freezer (220uC) until the
measurements.
Measurement of serum ACE2 activity
The sACE2 activity measurement was performed using a
specific quenched fluorescent substrate as previously described
with some modifications [25] [26] [27]. The reaction mixture (200
mL) contained 20 ml serum, 80 mL buffer and 100 ml (50 mM)
sACE2-specific fluorescent substrate (7-methoxycoumarin-4-yl)a-
cetyl-Ala-Pro-Lys(2,4-dinitrophenyl)-OH [Mca-APK(Dnp)] (EZ
Biolab, Carmel, USA). sACE2 activity was measured by fluoro-
metric assay of the enzymatic cleavage of K(Dnp) from the
fluorogenic substrate Mca-APK(Dnp).
The reaction buffer contained a protease inhibitor cocktail 10
mM Bestatin-hidrochloride, 10 mM Z-prolyl-prolinal (Enzo Life
Science, Exeter, UK), 5 mM Amastatin-hidrochloride, 10 mM
Captopril and 5 mM NaCI, 100 mM ZnCI2, 75 mM TRIS HCI,
pH 6.5. All chemicals were from Sigma (St. Louis, MO, USA) if
not stated otherwise.
The reaction was performed in black 96-well microtiter plates
(Greiner Bio-One, Frickenhauser, Germany). The assay was
monitored continuously by measuring the increase in fluorescence
(excitation wavelength = 320 nm, emission wavelength= 405 nm)
upon substrate hydrolysis using a fluorescence microplate reader
(NOVOstar; BMG Labtech GmbH, Offenburg, Germany). Initial
enzyme activities were determined from the linear rate of
fluorescence increase over the 0–120 min time course. The
increase in fluorescence was plotted as a function of reaction time
and fitted with a linear regression.
sACE2 activity was calculated by the equation:
sACE2 activity = (S/k)*D
where S is the rate of observed increase in fluorescence intensity,
k is the change in fluorescence intensity upon the complete
cleavage of 0.1 nmol of Mca-APK(Dnp), and D is the dilution of
the serum. 1 unit of fluorescence (UF) corresponds to the quantity
of enzyme which can degrade 0.1 nmol Mca-APK(Dnp) in 1 hour
at 37 uC. The specificity of the sACE2 enzyme activity assay was
tested by the specific human sACE2 inhibitor DX600, on a single
test sample, where DX600 resulted in a complete inhibition of
Mca-APK(Dnp) cleavage (Figure S1). Fits were accepted when r.
0.95.
Measurement of serum angiotensin converting enzyme
(ACE) activity
Assessment of ACE activity was based on the spectrophotomet-
ric measurement of FAPGG hydrolysis [28] [29]. The reaction
mixture (200 mL) contained 50 mL of serum, 0.5 mM FAPGG (N-
[3-(2-Furyl)acryloyl]-L-phenylalanyl-glycyl-glycine) (Sigma, St.
Louis, MO, USA) substrate, 300 mM sodium chloride, and
25 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic
acid) at pH 8.2. Measurement of ACE activity is based on the
change in the absorption at 340 nm when FAPGG hydrolyzed to
furylacryloyl-L-phenylalaline (FAP) and glycylglycine (GG). The
reaction was performed in 96-well plates (Greiner Bio-One,
Frickenhauser, Germany). Changes in FAPGG absorbance were
detected using a microplate reader (NOVOstar; BMG Labtech
GmbH, Offenburg, Germany). Hydrolysis of FAPGG by ACE was
recorded in every 5 minutes at 37Cu. Optical density values were
plotted as a function of reaction time and fitted by linear
regression. The fit and the data were accepted when r.0.9. ACE
activity was calculated by the equation:
ACE activity =2(S/k)*D,
where S is the rate of observed decrease in optical density (1/
min), k is the change in optical density upon the complete cleavage
of 1 nmol of FAPGG, and D is the dilution of the serum. One unit
(U) of ACE activity represents 1 nmol of FAPGG hydrolysis per
minute at 37 uC.
Measurement of serum ACE concentration
ACE concentration was determined using a Human ACE
enzyme-linked immunosorbent assay (ELISA) Development Sys-
tem (catalog No. DY929; R&D System, Inc, Minneapolis, USA)
according to the manufacturer’s instruction, with minor modifi-
cations [30]. In brief, enzyme–linked immunosorbent assay plates
were coated with capture antibody diluted to a working
concentration of 80 ng/well in Dulbecco’s modified phosphate-
buffered saline solution (DPBS) (Invitrogen Corp, Carlsbad, CA,
USA) overnight at room temperature. The remaining binding sites
were blocked with bovine serum albumin (Sigma, St. Louis, MO,
USA), 10 mg/mL, dissolved in DPBS. Human serum samples
were diluted 100-fold in the same buffer (10 mg/mL of bovine
serum albumin in DPBS) and incubated with the immobilized
primary antibodies for 2 hours. Capture antibody-bound ACE
was labeled using a biotinylated detection antibody, 20 ng/well for
2 hours. Streptavidin-conjugated horseradish-peroxidase (200-
fold-diluted stock from the kit) was added to the wells and
incubated for 20 minutes. The immunocomplexes were detected
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with a chromogenic substrate solution containing 0.3 mg/mL
TMB (3,3,59,59-tetramethylbenzidine), 0.1 mM H2O2 and 50 mM
acetic acid (incubation time was about 20 minutes). Reaction was
terminated by addition of 0.5 M HCl and was evaluated by
measuring absorbance at 450 nm. ACE concentration was
calculated using a calibration curve. The ACE concentration in
the samples were measured at least three times to achieve a
standard deviation of at most 15%. Serum ACE concentration was
given as ng/mL of serum.
N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)
measurements
NT-proBNP levels were measured in serum using a commer-
cially available kit (Elecsys proBNP II., Roche Ltd., Mannheim,
Germany).
Statistical analysis
Unpaired echocardiographic values were analyzed by the
nonparametric Kruskal-Wallis test (two tails, Figure 1A–C). With
these nonparametric tests there is a difference between the
hypertensive and healthy patients groups. Bars are mean 6
S.E.M. Significant differences are labeled by asterisks (** P,
0.001). Paired echocardiographic data (CRT before and after,
Figure 1A–1C) were evaluated by the nonparametric Wilcoxon
matched-pairs signed rank test (two tails). The dP/dt parameter
was analyzied with paired t-test (two tailes, Figure 1D).
Statistical differences in the biochemical parameters (figures
where soluble ACE2 activities are evaluated, Figure 2) were
addressed by the parametric ANOVA tests (comparison of all
group-pairs, Newman-Keuls post test).
Linear regression analysis was performed to compare sACE2
activity with echocardiographic parameters and NT-proBNP
levels (Figures 3–5). Linear regression analysis was performed to
compare serum ACE concentration with echocardiographic
parameters (Figure 6). P,0.05 was considered to be statistically
significant for all the comparisons. All statistical analyses were
performed using a commercially available software GraphPad
Prism, version 4.0 (GraphPad Software, Inc., San Diego, CA,
USA).
Results
Baseline characteristics of study groups
Clinical characteristics of the study groups are shown in Table 1.
The healthy (systolic/diastolic blood pressure: 122.5610.9/
79.569.8 mmHg) and the hypertensive group (optimal medical
therapy, systolic/diastolic blood pressure: 134.0619.9/
80.3611.5 mmHg) consisted of individuals with no apparent
symptoms and clinical signs of systolic or diastolic heart failure
(Table 1). The CRT group consisted of patients with mild (NYHA
II) to severe heart failure (NYHA III–IV) and matched ECG and
echocardiographic criteria for biventricular pacemaker implanta-
tion. The mean EF in the CRT group was seriously reduced
(Table 1) with enlarged end-systolic (ESD, Table 1) and end-
diastolic (EDD, Table 1) diameters. In all cases CRT-D device was
implanted. Significantly elevated NT-proBNP levels were found in
the hypertensive and CRT groups compared to the healthy group.
Occurrence of cardiovascular risk factors and medication in the
study population is also summarized in Table 1. The pharmaceu-
tical therapy remained unchanged during the study.
Effects of biventricular pacing on echocardiographic
parameters
Hypertensive and heart failure (HF) patients had significantly
enlarged initial left ventricular dimensions (ESD, EDD) before
cardiac resynchronization therapy (HF - CRT before) compared
to healthy individuals (Table 1, Figure 1A and 1B). Severe
reduction of left ventricular pumping function was observed as
represented by reduced EF in the CRT group (Table 1, Figure 1C).
A significant decrease of ESD and EDD (ESD to 51.961.4 mm;
P,0.001, EDD to 63.961.2 mm; P,0.01, Figure 1A and 1B) was
found following 6 to 9 months of biventricular pacing (HF – CRT
after). Pumping function also improved to a great extent in this
group (EF to 34.261.1%; P,0.001; Figure 1C). The dP/dt
parameter changed in a significant manner as well following CRT
(from 498.6627.1 to 695.4654.0 mmHg/s; P,0.001; Figure 1D).
sACE2 activity positively correlates with the clinical status
of systolic heart failure patients
A remarkable elevation of sACE2 activity was present in CRT
patients before pacemaker implantation (HF – CRT before)
compared to healthy people and to the hypertensive patients with
preserved left ventricular EF (healthy: 16.260.8 UF/mL, hyper-
tensive: 24.860.8 UF/mL and HF - CRT before: 30.261.7 UF/
mL, Figure 2A). Serum ACE2 activity strongly correlated with the
clinical condition of patients with severe heart failure (HF - CRT
before: NYHAII: 32.363.1 UF/mL, NYHAIII: 45.262.9 UF/
mL, NYHAIV: 64.266.2 UF/mL, Figure 2B).
The positive correlation between sACE2 and NYHA classes
remained unchanged after pacemaker implantation (HF - CRT
after: NYHAI: 25.862.5 UF/mL, NYHAII: 35.462.3 UF/mL,
NYHAIII: 45.966.0 UF/mL, Figure 2C), while the clinical status
improved in most of the HF-patients.
Angiotensin converting enzyme (ACE) expression was generally
lower in heart failure patients before CRT (healthy:
159.069.3 ng/mL, hypertensive: 149.666.9 ng/mL; HF - CRT
before: NYHA II: 102.066.4 ng/mL, NYHAIII: 103.766.3 ng/
mL, NYHAIV: 90.9610.2 ng/mL, Figure 2D), but this general
relationship disappeared after CRT (HF – CRT after: NYHAI:
114.6610.4 ng/mL; NYHAII: 128.368.5 ng/mL; NYHA III:
123.9622.9 ng/mL, Figure 2E).
sACE2 activity correlates with hypertension and with the
deterioration of left ventricular systolic function
Serum ACE2 activity correlated with the clinical status of HF.
Accordingly, we performed a detailed study to identify serum
ACE2 as a biomarker of human heart failure. Serum ACE2
activities were plotted as the function of systolic ejection fraction in
all study groups (Figure 3A, 3B and 3C). Serum ACE2 activities
negatively correlated with EF in hypertensive patients (Figure 3A)
similarly to HF patients (Figure 3C). In contrast, no correlation
was present between EF and sACE2 activity in healthy individuals
(Figure 3B). Moreover, a clear positive correlation was found
between serum ACE2 activities and ESD (Figure 3D) and EDD
(Figure 3E) in HF patients.
sACE2 activity correlates with the improvement in left
ventricular function
Serum ACE2 activity was higher in hypertensive patients
compared to healthy individuals (hypertensive: 24.860.9 UF/mL,
healthy: 16.260.8 UF/mL; P,0.0001, Figure 4A) and further
increased in HF patients (HF – CRT before: 42.562.9 UF/mL;
P,0.0001, Figure 4A), suggesting that sACE2 activity may be a
biomarker of cardiovascular disease or imminent heart failure. In
Circulating ACE2 in Human Heart Failure
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this respect, a good biomarker also correlates with the clinical
improvement of the disease. Correlation of sACE2 was therefore
also investigated upon the clinical improvement after biventricular
pacemaker implantation (HF- CRT after). A robust reduction in
serum ACE2 activity was found in parallel to the improving
cardiac performance and function called reverse remodeling (HF -
CRT after: to 34.361.9 UF/mL; P,0.001, Figure 4A).
Regression analyses of serum ACE2 as a function of EF after
CRT revealed that the correlation remained negative (P,0.01,
r = 0.46, Figure 4B), and positive correlation of sACE2 activity to
ESD and EDD was also preserved (ESD: P,0.01, r = 0.45; EDD:
P= 0.01, r = 0.3, Figure 4C and 4D).
Figure 1. Echocardiographic parameters of the study populations. Left ventricular echocardiographic parameters end systolic diameter (ESD,
panel A), end diastolic diameter (EDD, panel B) and ejection fraction (EF, panel C) are shown in healthy people (healthy, n = 45, filled bars), patients
with hypertension (hypertensive, n = 239, grey bars) and with severe heart failure (HF - CRT, n = 65, open bars). The kinetics of ventricular contractions
(dP/dt) is shown in patients with severe heart failure (panel D, n = 22). Values in patients undergoing cardiac resynchronization therapy are shown
before device implantation (HF - CRT, before) and after 6–9 months (HF - CRT, after). Unpaired echocardiographic values were analyzed by the
nonparametric Kruskal-Wallis test (two tails, panel A–C). Paired echocardiographic data (CRT before and after, panel A–C and dP/dt, panel D) were
evaluated by the nonparametric Wilcoxon matched-pairs signed rank test (two tails). Bars are mean 6 S.E.M. Significant differences are labeled by
asterisks (** P,0.001).
doi:10.1371/journal.pone.0087845.g001
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Figure 2. Differences in serum angiotensin converting enzyme activities and concentrations in study populations representing
various clinical status of heart failure. Serum ACE2 activity levels were determined in healthy people (healthy, n = 45, filled bar, panel A), patients
with no apparent heart failure (hypertensive, n = 239, grey bar, panel A) and in patients with severe systolic heart failure (HF - CRT before, n = 100,
open bars, panel A). Patients were also evaluated with respect of their New York Heart Association (NYHA) functional class (HF - CRT before: NYHAII:
n = 31; NYHAIII: n = 55; NYHAIV: n = 14, panel B; HF - CRT after: NYHAI: n = 17; NYHAII: n = 37; NYHAIV: n = 11, panel C). Serum ACE concentration was
Circulating ACE2 in Human Heart Failure
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Correlation of sACE2 activity with NT-proBNP
There was no correlation between sACE2 activity and NT-
proBNP in individuals with normal left ventricular systolic
function (healthy and hypertensive, Figure 5A and 5B). Serum
ACE2 activities positively correlated to NT-proBNP levels in HF
patients before CRT (HF – CRT before: P,0.01, r = 0.52,
Figure 5C). This positive correlation of sACE2 activity and NT-
proBNP was maintained after CRT (HF – CRT after: P,0.01,
r = 0.47, Figure 5D).
Correlation of serum ACE activity and concentration to
left ventricular systolic function
ACE activity of the cardiovascular patients (hypertensive:
14.560.9 U/mL, HF - CRT before: 14.262.0 U/mL and HF -
CRT after: 11.361.9 U/mL, Figure 6A) were significantly lower
than that in healthy individuals (healthy: 33.661.7 U/mL,
Figure 6A), most probably representing successful ACE inhibitory
therapy. Patients with severe systolic heart failure had significantly
lower enzyme concentration than patients with preserved EF
(healthy: 159.069.3 ng/mL, hypertensive: 149.666.9 ng/mL and
HF - CRT before: 100.565.3 ng/mL; P,0.001, Figure 6B).
Moreover, serum ACE concentration increased after pacemaker
implantation (HF – CRT after: to 123.166.5 ng/mL; P,0.01,
Figure 6B). Nevertheless, regression analyses of ACE concentra-
tion as a function of EF before CRT (HF - CRT before) or after
CRT (HF-CRT after) did not show any significant correlations
(Figure 6C–6H).
Discussion
One of the most frequent cardiovascular diseases is hyperten-
sion. It leads to secondary cardiomyopathy, coronary artery
disease, stroke, peripheral artery disease, chronic nephropathy,
neuropathy and many other severe pathologies and ultimately
increases mortality. Interestingly, most of the cases (up to 95%) do
not have identifiable cause (essential hypertension). It is important
to note, that there are effective treatments for hypertension,
making it a relatively easily manageable disease, but there is no
cure for it, which is probably related to the issue, that the very
also determined with respect of the New York Heart Association (NYHA) functional class of the patients before (HF – CRT before, panel D) and after
CRT (HF – CRT after, panel E). Statistical analyses of healthy people, hypertensive, HF - CRT before and HF – CRT after groups were performed by one-
way analysis of variance (ANOVA) followed by Newman-Keuls test for multiple comparisons between groups. Bars are mean 6 S.E.M. Significant
differences are labeled by asterisks (** P,0.001).
doi:10.1371/journal.pone.0087845.g002
Figure 3. Serum ACE2 activity correlates with left ventricular ejection fraction. Serum ACE2 activities were plotted as a function of left
ventricular ejection fraction (EF), in healthy people (healthy, n = 45, panel A), in patients with preserved EF (hypertensive, n = 239, panel B and in
patients with severe reduction in EF (HF - CRT before, n = 65, panel C). Serum ACE2 activities were also plotted as the function of the cardiac
morphological parameters end systolic diameter (ESD, panel D) and end diastolic diameter (EDD, panel E) in heart failure patients before CRT (HF –
CRT before). Each dot represents values of individual patients. Points were fitted by linear regression. The value P indicates the level of significance of
the positive correlation between the plotted parameters, while r represents a measure of the goodness of the fit.
doi:10.1371/journal.pone.0087845.g003
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Figure 4. Serum ACE2 activity correlates with reverse remodeling. Serum ACE2 activity was determined in healthy people (healthy, n = 45,
filled bar), patients with preserved ejection fraction (hypertensive, n = 239, grey bar) and in patients with severe heart failure before (HF – CRT before)
and after (HF – CRT after) cardiac resynchronization therapy (CRT, n = 65, open bars, panel A). Statistical analyses were performed by one-way analysis
of variance (ANOVA) followed by Newman-Keuls test for multiple comparisons between groups. Bars represent mean 6 S.E.M. Significant differences
between values are labeled by asterisks (** P,0.001). In addition, individual values for the patients after CRT (HF – CRT after) are also shown (panels
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cause of the disease is not known. As a result, patients are treated
and their blood pressure is kept at an acceptable level (target blood
pressure is reached by medication), but their background
pathology causing the hypertension may be unaffected.
Here we found for the first time that serum ACE2 activities are
increased in hypertensive patients (without apparent heart failure,
ejection fraction .50%) compared to healthy individuals.
Nonetheless, these hypertensive patients already had a barely
decreased ejection fraction compared to the healthy population
and also featured slightly elevated NT-proBNP levels, suggesting
that this population is at imminent heart failure. At this stage of
the disease serum ACE2 activity was already elevated although it
did not correlate with NT-proBNP levels. It appears therefore,
that serum ACE2 activity is another biomarker of imminent heart
failure in hypertension. Importantly, sACE2 may also be related to
the cause of the disease. It can regulate (decrease) local angiotensin
B–D). Serum ACE2 activities were plotted as a function of ejection fraction (EF, panel B), end systolic diameter (ESD, panel C) and end diastolic
diameter (EDD, panel D). Plots were fitted by linear regression and the goodness of fits is indicated by the ‘r’ values, while the correlations are
represented by the ‘P’ values.
doi:10.1371/journal.pone.0087845.g004
Figure 5. Positive correlation between sACE2 activity and NT-proBNP concentration. Serum ACE2 activities were plotted as the function
of NT Pro-Brain Natriuretic Peptide (NT-proBNP) concentrations in various study groups (healthy, n = 45, panel A, hypertensive, n = 239, panel B, HF -
CRT before, n = 100, panel C, HF - CRT after, n = 65, panel D). Each dot represents values of individual patients in these plots. Points were fitted by
linear regression. The value P indicates the level of significance of the positive correlation between the plotted parameters, while r represents a
measure of the goodness of the fit.
doi:10.1371/journal.pone.0087845.g005
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II levels, affecting vascular diameter (vascular smooth muscle
located angiotensin receptors) and sympathetic tone (neuronal
angiotensin receptors). It may also contribute to the synthesis of
angiotensin peptides which may activate the Mas receptor,
believed to be beneficial in hypertension. This hypothesis is
supported by recent findings suggesting that serum ACE is a rate-
limiting step in RAAS: endogenous inhibitors [31], such as serum
albumin [32] effectively (.90%) inhibit circulating ACE activity in
human.
Although this is the first time when increased sACE2 activity
was shown in hypertension in human, the potential connection
between sACE2 and regulation of blood pressure is not a new
concept. Previous animal data have shown that transgenic sACE2
overexpression in the vessels of SHRSP rats normalizes (reduces)
high blood pressure [11]. Modulation of sACE2 activity in the
nervous system (overexpression) also attenuated hypertension [12]
indicating a possibly protective role of sACE2 in hypertension.
Genetic inactivation of sACE2 was again found to be a negative
regulator of the RAS in blood pressure control [11] [13] [14].
Moreover, genetic association studies have shown a strong
association of sACE2 polymorphisms to hypertension in different
human populations [5] [16] [17], although without reference to
the actual effect of these polymorphisms on the circulating ACE2
activity. In this respect our study identified sACE2 activity as a
biomarker in imminent human heart failure.
The sACE2 was also implicated as a biomarker of definitive
heart failure in animal models where absence of sACE2 caused
severely impaired cardiac function [19] [20] [15] [30].
There is a wealth of information in human heart failure.
Myocardial sACE2 gene expression increased in patients with left
ventricular dysfunction including thinning of the left ventricle and
severe reduction in cardiac contractility [20]. Burrell et al.
observed an increase in sACE2 expression in failing human hearts
independently of AT1R blockade [31]. Loss of sACE2 worsened
the pathological remodeling and the systolic dysfunction [21]
Moreover, sACE2 gene expression increased in tissue samples of
patients with left ventricular dysfunction and serum ACE2 activity
was elevated and correlated with disease severity [26].
Here we made an effort to directly address the relationship
between serum ACE2 activity and cardiac function. Changes in
serum ACE2 activity were measured in severe heart failure when
cardiac resynchronization therapy (CRT) is indicated [24] [23].
We found significant relationships among plasma ACE2 activity
and both left ventricular ejection fraction (EF) and NT-proBNP
(Figure 5A) which were reported earlier by Epelman et al. [8]. Our
new data therefore repeat these findings. However, we also made a
detailed analysis of the relationship between serum ACE2 activity
and the echocardiographic systolic parameter EF at the individual
patient’s level (Figure 3). Serum ACE2 activity negatively
correlated with EF in patients with systolic HF (Figure 3C) as
well as in hypertensive patients with preserved EF (Figure 3A), but
not in healthy volunteers (Figure 3B).
In HF people serum ACE2 activity also correlated with the NT-
proBNP concentration, which is the most widely used molecular
marker of systolic HF with a reasonably high predictive and
prognostic value. It has been suggested that soluble ACE2 levels
are independent predictors of a composite end-point consisting of
all-cause mortality, cardiac transplantation and heart failure
hospitalization [26]. For the first time we have shown that NT-
proBNP concentration positively correlates with serum ACE2
activity at the individual patient’s level (Figure 5A). This particular
observation showed that there is no clearly identifiable patient
population with high NT-proBNP and relatively low sACE2 levels,
which has been suggested to be a better prognostic factor [26].
Furthermore this kind of relationship still exists when cardiac
function improves (Figure 5B).
Elevated circulating ACE2 level in systolic HF raise the question
whether serum ACE2 concentration is elevated due to a general
increase in sACE2 expression or the increasing soluble ACE2
activity represent a re-distribution of sACE2 from the tissues to the
serum. Higher rate of release from the cells may lead to lower
tissue sACE2 levels in parallel with increasing serum ACE2
activities in this latter case.
Data from animal models suggest that sACE2 shedding is
stimulated by the tumor necrosis factor-a convertase ADAM17.
Moreover, TACE/ADAM17 is upregulated in HF [9]. Therefore,
cleavage of membrane sACE2 may be due to the up-regulation of
a pathological protease related to proinflammatory mechanisms
during myocardial injury, resulting in the decrease of local
membrane sACE2 levels and an increase in tissue AngII levels,
while decreasing Ang-(1–7). These changes in the local concen-
trations of AngII and Ang-(1–7) can significantly contribute to
remodeling and to the deterioration of cardiac function (Figure 7).
A considerable part of currently used biomarkers are related to
a specific disease indirectly. Here we tested the soluble ACE2
activity for the first time when cardiac function is being improved,
but no change in drug therapy occurs. We found that soluble
ACE2 activity correlated well with the improvement of cardiac
function after implantation of a biventricular pacing device (CRT).
In particular, improving EF after CRT correlated negatively with
serum ACE2 activities (Figure 4A and 4B), improvement of
cardiac morphological parameters correlated positively with
sACE2 activities (ESD, Figure 4C and EDD, Figure 4D).
An effort was also made to correlate the soluble ACE levels to
cardiovascular disease. ACE expression changed with the
improvement of cardiac function. In particular, soluble ACE
concentration was lower before pacemaker implantation than in
the healthy individuals and in patients with hypertension with
preserved ejection fraction and it increased in parallel with the
improvement of cardiac function (Figure 6B). In spite of increased
soluble ACE concentrations soluble ACE activity did not change
in the diseased populations (Figure 6A) suggesting effective
therapeutical inhibition of ACE, besides to the recently shown
stabilizing effect of serum albumin on ACE activity [30].
Regression analyses of ACE concentration with EF, ESD and
EDD before and after CRT groups did not show any correlation
in spite to the promising correlation between soluble ACE
concentration and cardiovascular disease (Figure 6C–6H). More-
over, although ACE expression was lower in patients with heart
failure before CRT, this general relationship disappeared after
Figure 6. Serum ACE activity and concentration in patients with normal systolic left ventricular function and in patients with
systolic heart failure. Serum ACE activity (panel A) and ACE concentration (panel B) were measured in healthy people (n = 45, filled bar), in patients
with preserved ejection fraction (hypertensive, n = 40, grey bar) and in patients with severe heart failure before (HF - CRT before) and after cardiac
resynchronization therapy (HF - CRT after, n = 65, open bars). Statistical analyses of biochemical measurements was performed by one-way analysis of
variance (ANOVA) followed by Newman-Keuls test for multiple comparisons between groups. Bars represent mean6 S.E.M. Significant differences are
labeled by asterisks (* P,0.01 and ** P,0.001). Values for the individual patients were also plotted. Serum ACE concentration is showed as a function
of the ejection fraction (EF, panels C and D), end systolic diameter (ESD, panels E and F) and end diastolic diameter (EDD, panels G and H). Plots were
fitted by linear regression. Values for the goodness of the fits (r) and for the level of correlations (P) are also indicated.
doi:10.1371/journal.pone.0087845.g006
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CRT, when an improvement was observed in the clinical
parameters. These data suggested that ACE expression is not
related ultimately to the clinical status and severity of heart failure.
There is a significant interest about HF biomarkers. Many
candidates were proposed, including peptides, enzymes, receptors
of inflammatory system, changes in the extracellular matrix of
myocytes, oxidative stress and neurohormones [27,32]. Clinical
biomarker testing related to HF is aimed to identify possible
underlying causes, to confirm the presence or absence of HF and
to estimate the severity and the risk of disease progression,
according to the consensus document of The National Academy of
Clinical Biochemistry of the US [33]_ENREF_30. An ideal
biomarker does not only indicate the pathology but also takes
elemental part of that. Our data suggest that sACE2 is involved in
disease pathomechanism, it correlates well with disease severity
and even with regression of the disease so it is a candidate for HF
biomarker.
Based on these data we hypothesize that redistribution of ACE
and in particular sACE2 contribute to the pathomechanism of HF.
We found that soluble ACE concentration decreases, while soluble
ACE2 concentration increases in systolic HF suggesting an
opposite change in the tissue located forms of these enzymes.
These changes promote AngII formation in the tissues, contrib-
uting to AngII related pathologies. Therapeutical interventions
leading to improvement of cardiac function reverse the changes in
soluble enzyme concentrations (Figure 7). It is not clear yet,
whether these changes are consequences of HF, or important
contributors to the progression and reversion of the disease.
Nonetheless, this latter is supported by the clinical effectiveness of
ACE inhibitor drugs in the management of HF. Inhibition of the
redistribution of ACE enzymes therefore represents a new
therapeutic strategy to counterbalance tissue RAS activation.
Having said that we have to point out that this hypothesis is
limited by the lack of the direct measurement of tissue ACE and
sACE2 expression. It may also be possible that changes in the
serum concentrations of ACE and sACE2 represent changes in the
expression level of these proteins, rather than their redistribution.
This issue needs to be clarified by further clinical studies.
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Figure S1 Specificity of Mca-APK(Dnp) hydrolysis as a
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DX600 completely inhibited Mca-APK(Dnp) hydrolysis in a
concentration dependent manner in accordance with its inhibitory
activity on sACE2.
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